US EditionPublished • loading... • Updated
Emmaus Life Sciences Announces Strategic Transaction
Summary by Financial Post
4 Articles
4 Articles
Financial Post+2 Reposted by 2 other sources
Emmaus Life Sciences Announces Strategic Transaction
TORRANCE, Calif. -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced that it has entered into a License and Exclusive Distribution Agreement with NeoImmuneTech, Inc. (KOSDAQ:950220), or NIT, pursuant to which Emmaus has granted NIT an exclusive license to all rights to market, sell and distribute Endari® (prescription grade L-glutamine oral …
·Canada
Read Full Article
Coverage Details
Total News Sources4
Leaning Left0Leaning Right1Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
